-
公开(公告)号：US20220025032A1
公开(公告)日：2022-01-27
申请号：US17375860
申请日：2021-07-14
Applicant: NOVARTIS AG
Inventor： Chad Eric BIGELOW , Ana Maria CARRION , James Edgar CHASTAIN , Kirk Lee CLARK , Bijan Alexandre ETEMAD-GILBERTSON , Joy Gispati GHOSH , Shawn Michael HANKS , Nicole HAUBST , Ganesh Rajan IYER , Nina MOKER , Andrew Anh NGUYEN , Stephen Hendrick POOR , Yubin QIU , Nalini Velamur RANGASWAMY , Michael STEFANIDAKIS , Engin TOKSOZ , Michael Zbigniew TWAROG
Abstract: The present disclosure provides anti-BTC antibodies, methods of producing said antibodies, pharmaceutical compositions comprising said antibodies, and methods of using said antibodies. The present disclosure also provides multi-specific binding molecules, e.g., bispecific antibodies, comprising a BTC binding moiety and an anti-VEGF binding moiety.
-
2.发明申请公开(公告)号：US20200325218A1
公开(公告)日：2020-10-15
申请号：US16919020
申请日：2020-07-01
Applicant: NOVARTIS AG
Inventor： Barbara ANDLAUER , Matthew John EDWARDS , Kapil GUPTA , Nicole HAUBST , Rene HEMMIG , Daniel HUANG , Hans-Peter KNOPF , Danforth MILLER , Jean-Michel Rene RONDEAU , Gino Anselmus VAN HEEKE
Abstract: The invention provides molecules, e.g., antibodies or antibody fragments, that specifically bind thymic stromal lymphopoietin (TSLP), compositions comprising these molecules, and methods of using and producing these molecules.
-
公开(公告)号：US20190194347A1
公开(公告)日：2019-06-27
申请号：US16128057
申请日：2018-09-11
Applicant: NOVARTIS AG
Inventor： Winfried ELIS , Seth Alexander ETTENBERG , Andrew Paul GARNER , Nicole HAUBST , Christian Carsten Silvester KUNZ , Elizabeth Anne Reisinger SPRAGUE
IPC: C07K16/32 , C07K16/30 , A61K39/395 , A61K45/06
CPC classification number: C07K16/32 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/303 , C07K16/3038 , C07K16/3046 , C07K16/3053 , C07K16/3061 , C07K16/3069 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/76 , C07K2317/92 , A61K2300/00
Abstract: The present invention relates to antibodies or fragments thereof that target a conformational epitope of a HER receptor. In particular, the invention relates to antibodies or fragments thereof that target a conformational epitope of HER3 receptor and compositions and methods of use thereof.
-
4.发明申请公开(公告)号：US20180327489A1
公开(公告)日：2018-11-15
申请号：US15973735
申请日：2018-05-08
Applicant: NOVARTIS AG
Inventor： Matthew John EDWARDS , Jean-Michel Rene RONDEAU , Danforth MILLER , Daniel HUANG , Hans-Peter KNOPF , Gino Anselmus VAN HEEKE , Rene HEMMIG , Kapil GUPTA , Nicole HAUBST , Barbara ANDLAUER
Abstract: The invention provides molecules, e.g., antibodies or antibody fragments, that specifically bind thymic stromal lymphopoietin (TSLP), compositions comprising these molecules, and methods of using and producing these molecules.
-
公开(公告)号：US20160158358A1
公开(公告)日：2016-06-09
申请号：US14852003
申请日：2015-09-11
Applicant: NOVARTIS AG
Inventor： Winfried ELIS , Seth ETTENBERG , Andrew Paul GARNER , Nicole HAUBST , Xizhong HUANG , Christian Carsten Silvester KUNZ , Elizabeth Anne REISINGER SPRAGUE , Qing SHENG
IPC: A61K39/395 , A61K45/06 , C07K16/32 , C07K16/28
CPC classification number: A61K39/39558 , A61K31/4439 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K16/28 , C07K16/2863 , C07K16/32 , C07K2317/21 , C07K2317/55 , C07K2317/73 , C07K2317/76 , C07K2317/92 , A61K2300/00
Abstract: This invention relates to antibodies or fragments thereof which interact with HER family of receptors, e.g., HER3 receptor. In particular, it relates to antibodies or fragments thereof that recognize a conformational epitope of HER3 receptor comprising residues from both domains 2 and 4 resulting in inhibition of both ligand-dependent and ligand-independent signal transduction; and allow ligand binding (e.g., neuregulin), whilst preventing ligand-induced activation of signal transduction. These antibodies or fragments can be used to treat a number of diseases or disorders characterized by increased levels of HER3 expression (e.g., esophageal cancer). These antibodies or fragments can be used to treat a number of diseases or disorders characterized by the antibodys or fragments ability to decrease tissue weight (e.g., prostate or uterine weights) or to induce atrophy of tissue (e.g., atrophy of male breast).
-
Patent Agency Ranking
公开(公告)号：US20220356236A1
公开(公告)日：2022-11-10
申请号：US17809941
申请日：2022-06-30
Applicant: NOVARTIS AG
Inventor： Chad Eric BIGELOW , Ana Maria CARRION , James Edgar CHASTAIN , Kirk Lee CLARK , Bijan Alexandre ETEMAD-GILBERTSON , Joy Gispati GHOSH , Shawn Michael HANKS , Nicole HAUBST , Ganesh Rajan IYER , Nina MOKER , Andrew Anh NGUYEN , Stephen Hendrick POOR , Yubin QIU , Nalini Velamur RANGASWAMY , Michael STEFANIDAKIS , Engin TOKSOZ , Michael Zbigniew TWAROG
Abstract: The present disclosure provides anti-BTC antibodies, methods of producing said antibodies, pharmaceutical compositions comprising said antibodies, and methods of using said antibodies. The present disclosure also provides multi-specific binding molecules, e.g., bispecific antibodies, comprising a BTC binding moiety and an anti-VEGF binding moiety.
-
公开(公告)号：US20210008201A1
公开(公告)日：2021-01-14
申请号：US16940019
申请日：2020-07-27
Applicant: NOVARTIS AG
Inventor： Winfried ELIS , Seth Alexander ETTENBERG , Andrew Paul GARNER , Nicole HAUBST , Xizhong HUANG , Christian Carsten Silvester KUNZ , Elizabeth Anne REISINGER SPRAGUE , Qing SHENG
IPC: A61K39/395 , C07K16/32 , A61K45/06 , A61K31/4439 , C07K16/28
Abstract: This invention relates to antibodies or fragments thereof which interact with HER family of receptors, e.g., HER3 receptor. In particular, it relates to antibodies or fragments thereof that recognize a conformational epitope of HER3 receptor comprising residues from both domains 2 and 4 resulting in inhibition of both ligand-dependent and ligand-independent signal transduction; and allow ligand binding (e.g., neuregulin), whilst preventing ligand-induced activation of signal transduction. These antibodies or fragments can be used to treat a number of diseases or disorders characterized by increased levels of HER3 expression (e.g., esophageal cancer). These antibodies or fragments can be used to treat a number of diseases or disorders characterized by the antibodies or fragments ability to decrease tissue weight (e.g., prostate or uterine weights) or to induce atrophy of tissue (e.g., atrophy of male breast).
-
公开(公告)号：US20190216924A1
公开(公告)日：2019-07-18
申请号：US16115330
申请日：2018-08-28
Applicant: NOVARTIS AG
Inventor： Winfried ELIS , Seth Alexander ETTENBERG , Andrew Paul GARNER , Nicole HAUBST , Xizhong HUANG , Christian Carsten Silvester KUNZ , Elizabeth Anne REISINGER SPRAGUE , Qing SHENG
IPC: A61K39/395 , C07K16/28 , A61K45/06 , A61K31/4439 , C07K16/32
CPC classification number: A61K39/39558 , A61K31/4439 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K16/28 , C07K16/2863 , C07K16/32 , C07K2317/21 , C07K2317/55 , C07K2317/73 , C07K2317/76 , C07K2317/92 , A61K2300/00
Abstract: This invention relates to antibodies or fragments thereof which interact with HER family of receptors, e.g., HER3 receptor. In particular, it relates to antibodies or fragments thereof that recognize a conformational epitope of HER3 receptor comprising residues from both domains 2 and 4 resulting in inhibition of both ligand-dependent and ligand-independent signal transduction; and allow ligand binding (e.g., neuregulin), whilst preventing ligand-induced activation of signal transduction. These antibodies or fragments can be used to treat a number of diseases or disorders characterized by increased levels of HER3 expression (e.g., esophageal cancer). These antibodies or fragments can be used to treat a number of diseases or disorders characterized by the antibodys or fragments ability to decrease tissue weight (e.g., prostate or uterine weights) or to induce atrophy of tissue (e.g., atrophy of male breast).
-
公开(公告)号：US20130330324A1
公开(公告)日：2013-12-12
申请号：US13693330
申请日：2012-12-04
Applicant: NOVARTIS AG
Inventor： Winfried ELIS , Seth ETTENBERG , Andrew Paul GARNER , Nicole HAUBST , Xizhong HUANG , Christian Carsten Silvester KUNZ , Elizabeth Anne REISINGER SPRAGUE , Qing SHENG
IPC: A61K39/395 , A61K45/06
CPC classification number: A61K39/39558 , A61K31/4439 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K16/28 , C07K16/2863 , C07K16/32 , C07K2317/21 , C07K2317/55 , C07K2317/73 , C07K2317/76 , C07K2317/92 , A61K2300/00
Abstract: This invention relates to antibodies or fragments thereof which interact with HER family of receptors, e.g., HER3 receptor. In particular, it relates to antibodies or fragments thereof that recognize a conformational epitope of HER3 receptor comprising residues from both domains 2 and 4 resulting in inhibition of both ligand-dependent and ligand-independent signal transduction; and allow ligand binding (e.g., neuregulin), whilst preventing ligand-induced activation of signal transduction. These antibodies or fragments can be used to treat a number of diseases or disorders characterized by increased levels of HER3 expression (e.g., esophageal cancer). These antibodies or fragments can be used to treat a number of diseases or disorders characterized by the antibodys or fragments ability to decrease tissue weight (e.g., prostate or uterine weights) or to induce atrophy of tissue (e.g., atrophy of male breast).
Abstract translation: 本发明涉及与HER受体家族例如HER3受体相互作用的抗体或其片段。 特别地，其涉及识别包含来自结构域2和4的残基的HER3受体的构象表位的抗体或其片段，导致抑制配体依赖性和与配体无关的信号转导; 并允许配体结合（例如神经调节蛋白），同时防止信号转导的配体诱导的激活。 这些抗体或片段可用于治疗以增加的HER3表达水平为特征的许多疾病或病症（例如食道癌）。 这些抗体或片段可用于治疗以减少组织重量（例如前列腺或子宫重量）或诱导组织萎缩（例如雄性乳房萎缩）为特征的抗体或片段能力的许多疾病或病症。
-
公开(公告)号：US20220348646A1
公开(公告)日：2022-11-03
申请号：US17809943
申请日：2022-06-30
Applicant: NOVARTIS AG
Inventor： Chad Eric BIGELOW , Ana Maria CARRION , James Edgar CHASTAIN , Kirk Lee CLARK , Bijan Alexandre ETEMAD-GILBERTSON , Joy Gispati GHOSH , Shawn Michael HANKS , Nicole HAUBST , Ganesh Rajan IYER , Nina MOKER , Andrew Anh NGUYEN , Stephen Hendrick POOR , Yubin QIU , Nalini Velamur RANGASWAMY , Michael STEFANIDAKIS , Engin TOKSOZ , Michael Zbigniew TWAROG
Abstract: The present disclosure provides anti-BTC antibodies, methods of producing said antibodies, pharmaceutical compositions comprising said antibodies, and methods of using said antibodies. The present disclosure also provides multi-specific binding molecules, e.g., bispecific antibodies, comprising a BTC binding moiety and an anti-VEGF binding moiety.
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.024 seconds)
